(Q45736166)

English

Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus

scientific article published in August 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

cervix uterine cancer

1 reference

based on heuristic

inferred from title

Milton Weinstein

3

object named as

Weinstein MC

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Kenneth A. Freedberg

2

object named as

Freedberg KA

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

5

object named as

Kuntz KM

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

author name string

Goldie SJ

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Wright TC

4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

language of work or name

0 references

publication date

1 August 2001

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

American Journal of Medicine

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

111

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

140-149

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Human papillomavirus infection in women infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Incidence of cervical squamous intraepithelial lesions in HIV-infected women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. European Study Group on Natural History of HIV Infection in Women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Invasive cervical cancer in human immunodeficiency virus-infected and uninfected hospital patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

The epidemiology of cervical carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Natural history of cervicovaginal papillomavirus infection in young women.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Human papillomavirus testing in primary screening for cervical cancer of human immunodeficiency virus-infected women, 1990-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Survival from early, intermediate, and late stages of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Natural history of dysplasia of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

A longitudinal study of human papillomavirus DNA detection in human immunodeficiency virus type 1-seropositive and -seronegative women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Statistical analysis of the stages of HIV infection using a Markov model

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Determining costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Time costs associated with cervical cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Significance of mild cytologic atypia in women infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

The cost effectiveness of combination antiretroviral therapy for HIV disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Response to: Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy, by Heard et al. AIDS 1998, 12:1459-1464

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Toward consistency in cost-utility analyses: using national measures to create condition-specific values

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900780-X

7 January 2021

Identifiers

10.1016/S0002-9343(01)00780-X

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45736166&oldid=2079100617"